


Please type a plus sign (+) inside this box



Approved for use through 07/31/2005. OMB 0651-0031

PTO/SB/08A (07-05)

Substitute for form 1449A/PTO		<i>Complete if Known</i>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>		Application Number	10/501,933
		Filing Date	10/27/04
		First Named Inventor	MENDRICK
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
Sheet	1 of 24	Attorney Docket Number	GENE-035/15US

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code (if known)		
/LDR/ ↓	1.	5,811,231		Farr et al.	09-22-1998
	2.	5,858,659		Sapolsky et al.	01-12-1999
	3.	6,132,969		Stoughton et al.	10-17-2000
	4.	6,153,421		Yanagi et al.	11-28-2000
	5.	6,203,987		Friend et al.	03-20-2001
	6.	6,218,122		Friend et al.	04-17-2001
	7.	6,228,589		Brenner et al.	05-08-2001
	8.	6,365,352		Yerramilli et al.	04-2-2002
	9.	6,372,431		Cunningham et al.	04-16-2002
	10.	6,403,778		Cunningham et al.	06-11-2002
	11.	6,421,612		Agrafiotis et al.	07-16-2002
	12.	6,461,807		Friend et al.	10-8-2002
	13.	2001/0039006		Snodgrass	11-8-2001
	14.	2001/0049139		Lugasse et al.	12-6-2001
	15.	2002/0119462		Mendrick et al.	8-29-2002
	16.	2002/0142284		Riha et al.	11-3-2002
	17.	2003/0124552		Lindemann et al.	07-03-2003
	18.	2003/0154032		Pittman et al.	08-14-2003
	19.	2003/0028327		Brunner et al.	02-06-2003

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T
		Office	Number	Kind Code (if known)			
/LDR/ ↓	20.	WO	93/01205		The Salk Institute for Biological Studies	1-1-1993	
	21.	WO	94/17208		X-nometrix, Inc.	4-8-1994	
	22.	WO	97/13877		Lynx Therapeutics, Inc.	04-17-1997	
	23.	WO	99/27090		Smithkline Beecham Corporation	06-03-1999	
	24.	WO	99/43345		Eisai Co., Ltd., Beth Israel Deaconess Medical Center	09-02-1999	
	25.	WO	99/58670		Cidus Pharmaceuticals Corporation	11-18-1999	
	26.	WO	00/12760		Incyte Pharmaceuticals	9-3-2000	
	27.	WO	01/32928		Phase-1 Molecular Toxicology	05-10-2001	
28.	WO	01/25473		Source Precision Medicine, Inc.	04-12-2001		

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Unique citation designation number (optional). <sup>2</sup>See attached Kinds of U.S. Patent Documents. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.12. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH, /LDR/

Please type a plus sign (+) inside this box →

PTO/SB/08A (07-05)

Approved for use through 07/31/2006. OM B 0651-0031

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)	<i>Complete if Known</i>		
	Application Number	10/501,933	
	Filing Date	10/27/04	
	First Named Inventor	MENDRICK	
	Group Art Unit	Unassigned	
Examiner Name	Unassigned		
Sheet	5 of 24	Attorney Docket Number	GENE-035/15U5

**OTHER - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
/LDR/	94.	Chen et al., J. Environ. Pathol. Toxicol. Oncol., 14: 83-99 (1995) Abstract only
	95.	Chen, et al., Mol. Carcinog. 30:79-87, (2001)
	96.	Chisholm et al., Am. J. Physiol., 276: G1165-G1173 (1999)
	97.	Chou et al., Proc. Natl. Acad. Sci. U.S.A., 98: 8113-8118 (2001)
	98.	<del>Choudhury, G. et al., Environ. Health Perspect., 109: 1109-1116 (2001)</del> NIH press release dated 2/29/2001 found at www.nih.gov/news/rr/feb2001/nihhs-29.
	99.	Christian et al., Toxicol. Appl. Pharmacol., 82: 239-255 (1986)
	100.	Clive et al., Fundam. Appl. Toxicol., 3: 587-602 (1983)
	101.	Coles et al., Arch. Biochem. Biophys., 264: 253-260 (1988)
	102.	Conforti et al., Agents Actions, 40: 176-180 (1993)
	103.	Coni et al., Hepatology, 17: 1109-1116 (1993)
	104.	Copenhagen et al., Journal of Hepatology, 30: 1 pg. (1999)
	105.	Corell et al., Acta Pharmacol. Toxicol. (Copenh), 45: 232-239 (1979)
	106.	Corton & Stauber, Toxicol. Sci., 58: 217-219 (2000)
	107.	Corton et al., Biochimie., 79: 151-162 (1997)
	108.	Corton et al., Cancer Lett., 134: 61-71 (1998)
	109.	Corton et al., Cancer Lett., 137: 9-15 (1999)
	110.	Corton et al., Mol. Pharmacol., 54: 463-473 (1998)
	111.	Cronin, M.T.D., IL Farmaco, 56:149-151, (2001)
	112.	Crosby et al., Toxicol. Appl. Pharmacol., 169: 205-221 (2000)
	113.	Cunningham et al., Ann. N.Y. Acad. Sci., 919: 52-67 (2000)
	114.	Cunningham, M.J., J. of Pharmacol. And Toxicol. Methods, 44:291-300, (2000)
	115.	Cutler, P., et al., Electrophoresis, 20:3647-3658, (1999)

RC  
6/21/10

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Unique citation designation number (optional). \*See attached Kinds of U.S. Patent Documents. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /LDR/